Age and founder effect of SOD1 A4V mutation causing ALS
- PMID: 19176896
- PMCID: PMC2683645
- DOI: 10.1212/01.wnl.0000343509.76828.2a
Age and founder effect of SOD1 A4V mutation causing ALS
Abstract
Background: The alanine to valine mutation at codon 4 (A4V) of SOD1 causes a rapidly progressive dominant form of amyotrophic lateral sclerosis (ALS) with exclusively lower motor neuron disease and is responsible for 50% of SOD1 mutations associated with familial ALS in North America. This mutation is rare in Europe. The authors investigated the origin (geographic and time) of the A4V mutation.
Methods: Several cohorts were genotyped: North American patients with confirmed A4V mutation (n = 54), Swedish (n = 3) and Italian (n = 6) A4V patients, patients with ALS with SOD1 non-A4V mutations (n = 66) and patients with sporadic ALS (n = 96), healthy white (n = 96), African American (n = 17), Chinese (n = 53), Amerindian (n = 11), and Hispanic (n = 12) subjects. High-throughput SNP genotyping was performed using Taqman assay in 384-well format. A novel biallelic CA repeat in exon 5 of SOD1, tightly linked to A4V, was genotyped on sequencing gels. Association statistics were estimated using Haploview. p Values less than 0.05 were considered significant. Age of A4V was estimated using a novel method based on r(2) degeneration with genetic distance and a Bayesian method incorporated in DMLE+.
Results: A single haplotype of 10 polymorphisms across a 5.86-cM region was associated with A4V (p = 3.0e-11) when white controls were used, suggesting a founder effect. The strength of association of this haplotype progressively decreased when African American, Chinese, Hispanic, and Amerindian subjects were used as controls. The associated European haplotype was different from the North American haplotype, indicating two founder effects for A4V (Amerindian and European). The estimated age of A4V with the r(2) degeneration method was 458 +/- 59 years (range 398-569) and in agreement with the Bayesian method (554-734 years with 80-90% posterior probability).
Conclusions: North American SOD1 alanine to valine mutation at codon 4 descended from two founders (Amerindian and European) 400-500 years ago.
Figures
Comment in
-
SOD1 A4V familial ALS in North America: can understanding the past lead to a better future?Neurology. 2009 May 12;72(19):1628-9. doi: 10.1212/01.wnl.0000344651.66120.ea. Epub 2009 Jan 28. Neurology. 2009. PMID: 19176894 No abstract available.
Similar articles
-
SOD1 A4V familial ALS in North America: can understanding the past lead to a better future?Neurology. 2009 May 12;72(19):1628-9. doi: 10.1212/01.wnl.0000344651.66120.ea. Epub 2009 Jan 28. Neurology. 2009. PMID: 19176894 No abstract available.
-
SOD1A4V-mediated ALS: absence of a closely linked modifier gene and origination in Asia.Neurosci Lett. 2008 Jan 17;430(3):241-5. doi: 10.1016/j.neulet.2007.11.004. Epub 2007 Nov 6. Neurosci Lett. 2008. PMID: 18055113
-
Identification of an A4V SOD1 mutation in a Chinese patient with amyotrophic lateral sclerosis without the A4V founder effect common in North America.Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):466-468. doi: 10.1080/21678421.2018.1451895. Epub 2018 Mar 22. Amyotroph Lateral Scler Frontotemporal Degener. 2018. PMID: 29564924
-
Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis.Gene. 2016 Feb 15;577(2):109-18. doi: 10.1016/j.gene.2015.11.049. Epub 2015 Dec 2. Gene. 2016. PMID: 26657039 Review.
-
Estimated Prevalence and Incidence of Amyotrophic Lateral Sclerosis and SOD1 and C9orf72 Genetic Variants.Neuroepidemiology. 2021;55(5):342-353. doi: 10.1159/000516752. Epub 2021 Jul 9. Neuroepidemiology. 2021. PMID: 34247168 Review.
Cited by
-
Discovery of Novel Inhibitors against ALS-Related SOD1(A4V) Aggregation through the Screening of a Chemical Library Using Differential Scanning Fluorimetry (DSF).Pharmaceuticals (Basel). 2024 Sep 27;17(10):1286. doi: 10.3390/ph17101286. Pharmaceuticals (Basel). 2024. PMID: 39458929 Free PMC article.
-
Recent Progress of Antisense Oligonucleotide Therapy for Superoxide-Dismutase-1-Mutated Amyotrophic Lateral Sclerosis: Focus on Tofersen.Genes (Basel). 2024 Oct 20;15(10):1342. doi: 10.3390/genes15101342. Genes (Basel). 2024. PMID: 39457466 Free PMC article. Review.
-
Variability in SOD1-associated amyotrophic lateral sclerosis: geographic patterns, clinical heterogeneity, molecular alterations, and therapeutic implications.Transl Neurodegener. 2024 May 29;13(1):28. doi: 10.1186/s40035-024-00416-x. Transl Neurodegener. 2024. PMID: 38811997 Free PMC article. Review.
-
High-Fidelity Assay Based on Turn-Off Fluorescence to Detect the Perturbations of Cellular Proteostasis.ACS Bio Med Chem Au. 2024 Jan 19;4(2):111-118. doi: 10.1021/acsbiomedchemau.3c00012. eCollection 2024 Apr 17. ACS Bio Med Chem Au. 2024. PMID: 38645930 Free PMC article.
-
Unraveling the Genetic Landscape of Neurological Disorders: Insights into Pathogenesis, Techniques for Variant Identification, and Therapeutic Approaches.Int J Mol Sci. 2024 Feb 15;25(4):2320. doi: 10.3390/ijms25042320. Int J Mol Sci. 2024. PMID: 38396996 Free PMC article. Review.
References
-
- Tandan R, Bradley WG. Amyotrophic lateral sclerosis, part 1: clinical features, pathology, and ethical issues in management. Ann Neurol 1985;18:271–280. - PubMed
-
- Tandan R, Bradley WG. Amyotrophic lateral sclerosis, part 2: etiopathogenesis. Ann Neurol 1985;18:419–431. - PubMed
-
- Bobowick AR, Brody JA. Epidemiology of motor neuron diseases [review]. N Engl J Med 1973;288:1047–1055. - PubMed
-
- Nelson LM. Epidemiology of ALS. Clin Neurosci 1995;3:327–331. - PubMed
-
- Siddique T, Figlewicz DA, Pericak-Vance MA, et al. Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med 1991;324:1381–1384. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous